1. Home
  2. SLDP vs IRWD Comparison

SLDP vs IRWD Comparison

Compare SLDP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$3.11

Market Cap

848.8M

Sector

Energy

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.48

Market Cap

741.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
IRWD
Founded
2011
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
848.8M
741.8M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
SLDP
IRWD
Price
$3.11
$3.48
Analyst Decision
Strong Buy
Hold
Analyst Count
1
5
Target Price
$7.00
$4.94
AVG Volume (30 Days)
3.8M
2.8M
Earning Date
01-01-0001
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.15
Revenue
N/A
$298,276,000.00
Revenue This Year
$13.88
$57.95
Revenue Next Year
$10.00
$4.39
P/E Ratio
N/A
$24.03
Revenue Growth
N/A
8.88
52 Week Low
$0.68
$0.55
52 Week High
$8.86
$5.78

Technical Indicators

Market Signals
Indicator
SLDP
IRWD
Relative Strength Index (RSI) 30.58 38.14
Support Level $2.92 $3.08
Resistance Level $4.70 $3.53
Average True Range (ATR) 0.19 0.35
MACD 0.00 -0.07
Stochastic Oscillator 3.29 27.27

Price Performance

Historical Comparison
SLDP
IRWD

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Share on Social Networks: